Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2006-06-20
2006-06-20
Housel, James C. (Department: 1648)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C435S235100, C424S199100, C424S204100, C424S205100, C424S231100, C424S093100
Reexamination Certificate
active
07063835
ABSTRACT:
The present invention relates to non-laboratory virus strains, for example of herpes viruses such as HSV, with improved oncolytic and/or gene delivery capabilities as compared to laboratory virus strains.
REFERENCES:
patent: 5328688 (1994-07-01), Roizman
patent: 5585096 (1996-12-01), Matuza et al.
patent: 5876923 (1999-03-01), Leopardi et al.
patent: 6428968 (2002-08-01), Molnar-Kimber et al.
patent: WO 92 13943 (1992-08-01), None
patent: WO 97 04804 (1997-02-01), None
patent: 97/20935 (1997-06-01), None
patent: WO 97 26904 (1997-07-01), None
patent: 98/04726 (1998-02-01), None
patent: 98/37905 (1998-09-01), None
patent: 98/51809 (1998-11-01), None
patent: WO 99/38955 (1999-08-01), None
patent: WO 00/08191 (2000-02-01), None
patent: 00/40734 (2000-07-01), None
patent: WO 01/46449 (2001-06-01), None
patent: WO 01/46450 (2001-06-01), None
patent: WO 01/53505 (2001-07-01), None
patent: WO 01/53507 (2001-07-01), None
Mullen et al., The Oncologist, vol. 7, pp. 106-119 (2002).
Fulci et al., Frontiers in Bioscience vol. 8, pp. e346-360 (2003).
Coukos et al., Cancer Gene Therapy, vol. 5, No. 6 (Supp), p. S7 (Nov. 1998).
Toyoizumi et al., Cancer Gene Therapy, vol. 5 No. 6 (Supp), pp. S7-S8 (Nov. 1998).
Goldsmith et al., Journal of Experimental Medicine, vol. 187 No. 3, pp. 341-358 (Feb. 1998).
Bowie et al., Science, vol. 247 No. 4948, pp. 1306-1310 (Mar. 1990).
Ace et al. (1989) “Construction and characterisation of a herpes simplex virus type 1 mutant unable to transinduce immediate early gene expression” J. Virology 63:2260-2269.
Chou et al. (1990) “Mapping of herpes simplex virus-1 neurovirulence to γ34.5, a gene nonessential for growth in culture” Science 250:1262-1266.
DeLuca et al. (1985) “Isolation and characterisation of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4” J. Virology 56:558-570.
Gossen et al. (1995) “Transcriptional activation by tetracyclines in mammalian cells” Science 268:1766-1769.
Gossen & Bujard (1992) “Tight control of gene expression in mammalian cells by tetracyline-responsive promoters” Proc. Nat. Acad. Sci. USA 89-5547-5551.
Howard et al. (1998) “High efficiency gene transfer to the central nervous system of rodents and primates using herpes virus vectors lacking functional ICP27 and ICP34.5” Gene Therapy 5:1137-1147.
Hunter et al. (1999) “Attenuated replication-competent herpes simplex virus type 1 mutant G207:Safety evaluation of intracerebral injection in non-human primates” J. Virology 73:6319-6326.
Krisky et al. (1998) “Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons” Gene Therapy 5:1593-1603.
Maclean et al. (1991) “Herpeas simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+between immediate early gene 1 and the “a” sequence” J. Gen. virology 72:631-639.
MacFarlane et al. (1992) “Hexamethylene bisacetamide stimulates herpes simplex virus immediate early gene expressions in the absence of trans-induction by Vmw65” J. Gen. Virology 73:285-292.
Meignier et al. (1988) “In vivo behaviour of genetically engineered herpes simplex viruses R7017 and R7020: Construction and evaluation in rodents” J. Infect. Dis. 159:602-614.
Rice & Knipe (1990) “Genetic evidence for two distinct transactivation functions of the herpes simplex virus and protein ICP27” J. Virology 64:1704-1715.
Samaniego et al. (1995) “Functional interactions between herpes simplex virus immediate-early proteins during infection: Gene expression as a consequence of ICP27 and different domains of ICP4” J. Virology 69:5705-5715.
Samaniego et al. (1998) “Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins” J. Virology 72:3307-3320.
Smiley & Duncan (1997) “Truncation of the C-terminal acidic transcriptional activation domain of herpes simplex virus VP16 Produces a phenotype similar to that of the in1814 linker insertion mutation” J. Virology 71:6191-6193.
Smith et al. (1992) “Evidence that the herpes simplex virus immediate early protein ICP27 acts post-transcriptionally during infection to regulate gene expression” Virology 186:74-86.
Thomas et al. (1999) “Herpes simplex virus latency associated transcript encodes a protein which greatly enhances virus growth, can compensate for deficiencies in immediate-early gene expression, and is likely to function during reactivation from virus latency” J. Virology 73:6618-6625.
Chambers et al; “Comparison of Genetically Engineered Herpes Simplex Viruses for the Treatment of Brain Tumors in a Mouse Model of Human Malignant Glioma”; Proceeding of the National Academy of Sciences of USA, vol. 92, No. 5, Feb. 28, 1995, pp. 1411-1415, XP002090032.
Andreansky et al. (1997); “Evaluation of genetically engineered herpes simplex viruses a oncolytic agents for human malignant brain tumors” Cancer Res. 57(8): 1502-1509.
Ejercito et al. (1968); “Characterisation of herpes simplex virus strains differing in their effects on social behaviour of infected cells.” J. Gen. Virol. 2: 357-364.
Krisky et al. (1998); “Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications” Gene Therapy 5(11): 1517-1530.
Lachmann & Efstathiou (1999); “Gene transfer with herpes simplex vectors” Curr. Opin. Mol. Ther. 1(5): 622-632.
Moriuchi et al. (1998); “Enhanced tumor cell killing in the presence of ganciclovir by herpes simplex virus type 1 vector-directed coexpression of human tumor necrosis factor-alpha and herpes simplex thymidine kinase” Cancer Res. 58(24): 5731-5737.
Randazzo et al. (1996) “Herpes simplex 1716 an ICP 34.5 mutant is severely replication restricted in human skin xenografts in vivo” Virology 223(2): 392-395.
Speck et al. (1996); “The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors” J. Gen. Virol. 77(10): 2563-2568.
Andreansky et al, “The Application of Genetically Engineered Herpes Simplex Viruses to the Treatment of Experimental Brain Tumors,” Proc. Natl. Acad. Sci. vol. 93, pp. 11313-11318 (Oct. 1996).
Chou et al, “The γ134.5 Gene of Herpes Simplex Virus 1 Precludes Neuroblastoma Cells from Triggering Total Shutoff of Protein Synthesis Characteristic of Programmed cell Death in Neuronal Cells,” Proc. Natl. Acad. Sci. vol. 89, pp. 3266-3270 (Apr. 1992).
Chou et al, “Differential response of Human Cells to Deletions and Stop Condons in the Y134.5 Gene of Herpes Simplex virus,” Journal of Virology, pp. 8304-8311 (Dec. 1994).
Coukos et al, “Oncolytic Herpes Simplex Virus-1 Lacking ICP34.5 Induces p53-independent Death and Is Efficacious against Chemotherapy-resistant Ovarian Cancer,” Clinical Cancer Research vol. 6, pp. 3342-3353 (Aug. 2000).
Ezzeddine et al, “Selective Killing of Glioma Cells in Culture and in Vivo by Retrovirus Transfer of the Herpes Simplex Virus Thymidine Kinase Gene,” The New Biologist vol. 3, No. 6, pp. 608-614 (Jun. 1991).
Markert, James et al, “Reduction and Elimination of Encephalitis in an Experimental Glioma Therapy Model with attenuated Herpes Simplex Mutants that Retain Susceptibility to Acyclovir,” Neurosurgery vol. 32 No. 4, pp. 597-603.
Martuza et al, “Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant,” Science vol. 252, pp. 854-856.
McKie et al, “Selective in Vitro Replication of Herpes Simplex Virus 1 (HSV-1) ICP34.5 Null Mutants in Primary Human CNS Tumours—Evaluation of a Potentially Effective Clinical Therapy,” B
Biovex Limited
Housel James C.
Lucas Zachariah
LandOfFree
Virus strains does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Virus strains, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Virus strains will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3699241